Comparison effect of migroherb herbal drug( Tanacetum parthenium, Matricaria chamomilla and magnesium) and Venlafaxine in migraine

Comparison effect of migroherb herbal drug( Tanacetum parthenium, Matricaria chamomilla and magnesium) and Venlafaxine on the severity and frequency of headache and the quality of life of migraine sufferers

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231009059670N1

Enrollment

Registered

2024-02-19

Start date

2023-12-06

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine. Migraine

Interventions

Intervention 1: Intervention group: The recipient of venlafaxine capsules 37.5 mg daily along with sodium valproate 200 mg daily. The duration of this intervention is three months. Intervention 2: Int

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Ages 18-65 years Confirmation of episodic migraine by a neurologist according to the latest ICHD definition

Exclusion criteria

Exclusion criteria: Use of corticosteroids Use of vitamin D, calcium and riboflavin supplements Using other anti-migraine drugs (including beta-blockers, anti-seizures, calcium blockers, tricyclic antidepressants, nerve block or stimulation) except sodium valproate 200 mg daily Presence of tension headache Diagnosis of chronic migraine Having a history of liver, kidney and hyper parathyroid diseases Pregnancy and breastfeeding People with trigeminal autonomic cephalalgia and neuralgia People with secondary headaches Patients using OCP and undergoing HRT treatment Migraine headache onset age after 50 years Excessive consumption of alcohol and drugs Known cases of psychosis, major depression, bipolar disorder

Design outcomes

Primary

Measure	Time frame
Impact on quality of life. Timepoint: At the beginning of the study (before the start of the intervention) and one month, two months and three months after the start of Migroherb or Venlafaxine. Method of measurement: HIT6 (Headache Impact Test) questionnaire.;Headache attacks frequency. Timepoint: At the beginning of the study (before the start of the intervention) and three months after the start of migroherb or venlafaxine. Method of measurement: MIDAS (Migraine Disability Assessment) questioner.;Severity of headache attacks. Timepoint: At the beginning of the study (before the start of the intervention) and three months after the start of migroherb or venlafaxine. Method of measurement: MIDAS (Migraine Disability Assessment) questioner.	—

Measure

Time frame

Impact on quality of life. Timepoint: At the beginning of the study (before the start of the intervention) and one month, two months and three months after the start of Migroherb or Venlafaxine. Method of measurement: HIT6 (Headache Impact Test) questionnaire.;Headache attacks frequency. Timepoint: At the beginning of the study (before the start of the intervention) and three months after the start of migroherb or venlafaxine. Method of measurement: MIDAS (Migraine Disability Assessment) questioner.;Severity of headache attacks. Timepoint: At the beginning of the study (before the start of the intervention) and three months after the start of migroherb or venlafaxine. Method of measurement: MIDAS (Migraine Disability Assessment) questioner.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHodasadat Homayouni

Kashan University of Medical Sciences

hoda.homahoni91@gmail.com+98 31 3661 7507

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026